Mars completes stake acquisition in French veterinary players
The multinational has added Cerba Vet and ANTAGENE to its pet care portfolio.
Mars announced that it has completed its previously announced acquisition of Cerba HealthCare’s ownership stake in Cerba Vet and ANTAGENE.
Both businesses will join the Mars Science & Diagnostics division, along with the veterinary diagnosis business Antech and cat and dog genetic player Wisdom Panel.
It is expected that the acquisition will help Mars enhance the reach of its veterinary diagnostics business to European-based veterinarians and drive its research and development (R&D) capabilities.
Successful discussions
Mars started “exclusive discussions” with Cerba HealthCare Group, a network of 6 veterinary diagnostics laboratories in France and Switzerland, to acquire its stake in both companies.
Emmanuel Ligner, CEO of Cerba HealthCare, called Mars Science & Diagnostics “the right investor” as it would support the long-term development and growth of the businesses.
Share this story:
